AZN.L : Summary for ASTRAZENECA PLC ORD SHS $0.25 - Yahoo Finance

U.S. Markets closed

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
4,688.00+25.50 (+0.55%)
At close: 5:10PM BST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close4,662.50
Bid4,565.00 x 6100
Ask4,720.00 x 13000
Day's Range4,634.00 - 4,783.29
52 Week Range3,680.00 - 5,505.00
Avg. Volume2,532,685
Market Cap59.33B
PE Ratio (TTM)16.99
Earnings DateN/A
Dividend & Yield2.80 (4.81%)
Ex-Dividend DateN/A
1y Target EstN/A
  • Tesaro Inc Bulls Need a Reality Check
    Motley Fool7 hours ago

    Tesaro Inc Bulls Need a Reality Check

    Has the market overestimated the odds of success for Tesaro's fancy new cancer drug?

  • Reuters14 hours ago

    AstraZeneca moving costs rise as new HQ nears completion

    AstraZeneca's move to the English university city of Cambridge will cost more and take longer than initially expected, following increased expenditure on new technology and equipment. Investment in Cambridge, where AstraZeneca is building a strategic R&D centre and global corporate headquarters, is now expected to be more than 500 million pounds ($640 million), the drugmaker said on Tuesday. For Chief Executive Pascal Soriot, the new site on the Cambridge Biomedical Campus symbolizes his desire to create a science-led company with uniquely close ties to academia.

  • Reuters2 days ago

    EU drugmakers urge June decision on new location for watchdog

    Europe's drugmakers pushed for a decision as early as June on the new location for the headquarters of the bloc's medicines watchdog, which will relocate from London after Britain's decision to leave the EU. The new location will be decided by the EU's heads of state, whose next meeting as the European Council is scheduled for June 22-23. "The Council's deliberations on the Agency's future location need to be conducted on the basis of very essential criteria and put for decision as early on as possible, preferably at its meeting in June this year," European pharma lobby group EFPIA said in a statement on Monday signed by 19 top executives at member companies including Pfizer, Novartis, Sanofi and Roche.